Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue

Study Overview
=================
Brief Summary
-----------------
This retrospective study is to collect and analyze the data from medical records within the period that breast cancer patient is receiving NHI-covered CRF treatment. This study will evaluate the clinical use, fatigue improvement, and treatment satisfaction of breast cancer patients with CRF treatment.

Detailed Description
-----------------
This is a single arm, multicenter, and retrospective study. About 200 breast cancer patients' data from medical records are expected to collect and analyze in this retrospective study. The data collection from medical records of breast cancer patients who approved to use NHI to pay for CRF treatment drug will include the demographic information, disease characteristics and cancer treatment information, fatigue score by visual analog fatigue scale, fatigue clinical global impression, CRF pharmacological treatment record, hematological lab data, ECOG, cancer drug compliance record, overall clinical evaluation after CRF treatment by physicians and patient's expectation to continue CRF treatment etc. Data of three return visits (i.e. at the time of before CRF treatment, after 4 times of CRF treatment and CRF treatment completed) per patient will be collected from medical records to analysis within the period that patient is receiving NHI-covered CRF treatment.

Official Title
-----------------
Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue

Conditions
-----------------
Cancer-related Fatigue

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: breast cancer patients who approved to use NHI to pay for cancer-related fatigue treatment drug Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast cancer patients with Cancer-related fatigue treatment<br>Breast cancer patients who approved to use NHI to pay for Cancer-related fatigue treatment drug | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue Improvement |  | through study completion, an average of 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Level of Fatigue Clinical Global Impression-Improvement |  | through study completion, an average of 4 months | 
| Physician Satisfaction Degree of Overall Clinical Evaluation |  | 1 time, average of 4 months after baseline (at the end of study) | 
| Patient Expectation Rating of Continuous Cancer-Related Fatigue Treatment |  | 1 time, average of 4 months after baseline (at the end of study) | 
| ECOG Change |  | through study completion, an average of 4 months | 
| Weight Change |  | through study completion, an average of 4 months | 
| Hematological Lab Data Change |  | through study completion, an average of 4 months | 
| The Incidence of Cancer Treatent Delay |  | through study completion, an average of 4 months | 
| The Incidence of Cancer Treatent Dose Modification |  | through study completion, an average of 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer-related Fatigue, breast cancer